Proton pump inhibitors for functional dyspepsia (Q36300366)

2 July 2019

meta-analysis

0 references

title

Proton pump inhibitors for functional dyspepsia. (English)

1 reference

2 July 2019

4

Paul Moayyedi

1 reference

2 July 2019

Maria Ines Pinto-Sanchez

series ordinal

1

1 reference

2 July 2019

Yuhong Yuan

series ordinal

2

1 reference

2 July 2019

Premysl Bercik

series ordinal

3

1 reference

2 July 2019

publication date

8 March 2017

1 reference

2 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

2 July 2019

volume

3

1 reference

2 July 2019

page(s)

CD011194

1 reference

2 July 2019

Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Patient adherence to prescribed medication instructions for dyspepsia: the DIAMOND-study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori-Negative Primary Care Patients with Dyspepsia in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Classification of dyspepsia and response to treatment with proton-pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Irritable bowel disease with flatulence: is the breath test for carbohydrate malabsorption obligatory? Pro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Pretreatment prediction of symptom response to proton pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Adverse Event Reporting for Proton Pump Inhibitor Therapy: An Overview of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Long-term improvement in functional dyspepsia using hypnotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Current management strategies and emerging treatments for functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

The functional gastrointestinal disorders and the Rome III process

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Review article: current treatment options and management of functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Functional dyspepsia: the economic impact to patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Pharmacological interventions for non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Pharmacological interventions for non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Pharmacological interventions for non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

21 January 2018

Gastroduodenal Disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Proton-pump inhibitors for the treatment of functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Perils and pitfalls of long-term effects of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Safety of proton pump inhibitor exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011194.PUB2

Which dyspepsia patients will benefit from omeprazole treatment? Analysis of a Danish multicenter trial.

21 January 2018

1 reference

12 December 2020

Identifying responders to acid suppression in dyspepsia using a random starting day trial

1 reference

12 December 2020

A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.

1 reference

12 December 2020

Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type

1 reference

12 December 2020

Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confirmatory acid suppression test (CAST) study: further psychometric validation of the reflux disease questionnaire

1 reference

12 December 2020

Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia

1 reference

12 December 2020

Drug treatment of functional dyspepsia

1 reference

12 December 2020

Effectiveness of Ultop 10 mg using at treatment of functional (nonulcer) dyspepsia syndrome

1 reference

12 December 2020

[Long-term efficacy and safety research on functional dyspepsia treated with electroacupuncture and Zhizhu Kuanzhong capsule].

1 reference

12 December 2020

Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease

1 reference

12 December 2020

[Treatment of functional dyspepsia by Chinese medical syndrome typing: a randomized control research]

1 reference

12 December 2020

Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan

1 reference

12 December 2020

1 reference

12 December 2020

Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia

1 reference

12 December 2020

Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying

1 reference

12 December 2020

Review article: functional dyspepsia--should treatment be targeted on disturbed physiology?

1 reference

12 December 2020

Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia

1 reference

12 December 2020

Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study.

1 reference

12 December 2020

[Gastric acid secretion inhibitors: H2 receptor antagonists (H2RA), proton pump inhibitors (PPI) or acid pump antagonists (APA)]

1 reference

12 December 2020

Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia.

1 reference

12 December 2020

Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia

1 reference

12 December 2020

10.1002/14651858.CD011194.PUB2

Identifiers

DOI

1 reference

2 July 2019

PMCID

6464600

1 reference

2 July 2019

PubMed ID

28271513

1 reference

2 July 2019